A Scare That Stalled a Vaccine for Decades

Group A Streptococcus (GAS) causes approximately 800 million infections per year, including 616 million cases of pharyngitis, 111 million skin infections, and over 650,000 severe invasive cases with ~25% case fatality. Its downstream consequence — rheumatic heart disease (RHD) — affects at least 15.6 million people and kills ~320,000 per year, making GAS one of the top 10 infectious killers globally. Yet no vaccine exists. In the 1960s-70s, early vaccine trials were linked to reports of rheumatic fever, leading the FDA to place a de facto moratorium on GAS vaccine clinical trials in 1979. Though lifted in 2006, this created a 27-year gap in development, and the field has never recovered momentum. Only ~8 candidates are now in development, most in early clinical stages.

97% of invasive GAS cases and 95% of acute rheumatic fever occur in less developed countries. Two-thirds of people with RHD are women, with disproportionate impact during pregnancy. GAS has been called "the biggest infectious killer that no one has heard of." Modeling suggests vaccination at birth across 30 cohorts could avert 2.5 billion pharyngitis episodes and 6 million RHD cases. The 2018 World Health Assembly adopted a resolution on RHD, and WHO published Preferred Product Characteristics, but the vaccine pipeline remains thin relative to the burden.

The primary technical barrier is serotype diversity: over 200 distinct GAS emm types exist, and their distribution varies dramatically by geography. A 30-valent M protein vaccine (StreptAnova) would cover ~75% of strains in North America but only ~28% in East Africa, where burden is highest. The M protein — the most immunogenic target — shares epitopes with human cardiac tissue, creating the autoimmunity risk that originally halted the field. Conserved-region approaches (StrepInCor, J8/S2) aim to bypass serotype diversity but have not yet demonstrated efficacy. Non-M protein approaches (Group A carbohydrate, SpyCEP) avoid autoimmunity concerns but are earlier in development. No validated correlate of protection exists, making clinical trial design difficult. Proving efficacy against RHD — the primary burden driver — would require enormous multi-year trials, since RHD develops over years from repeated GAS exposures.

The WHO PPC specifies: broad serotype coverage across diverse geographic settings, no induction of autoimmune sequelae, suitability for LMIC immunization programs, and ideally efficacy against the full disease spectrum (pharyngitis, skin infections, downstream ARF/RHD). Two strategic paths are being pursued: (1) multivalent M protein vaccines that accept partial coverage but achieve cross-opsonic activity against non-vaccine serotypes, and (2) conserved antigen approaches (M protein C-terminus, Group A carbohydrate, surface enzymes) that are serotype-independent but immunologically less characterized. StreptAnova (30-valent) completed Phase 1 in 2020 with no autoimmune signals and is exploring an mRNA formulation. The Strep A Vaccine Global Consortium (SAVAC) coordinates global efforts.

A team could analyze the geographic distribution of GAS emm types using publicly available molecular epidemiology databases, mapping the predicted coverage of current vaccine candidates (StreptAnova 30-valent, conserved-region vaccines) across high-burden LMIC populations and identifying the serotype coverage gap. This would directly inform whether geography-specific vaccine formulations are needed. Alternatively, a team could develop an in silico model of cross-opsonic antibody responses to M protein variants, predicting which conserved epitopes generate the broadest cross-protection. Relevant disciplines: computational biology, immunology, epidemiology, global health.